X
High cost of cancer drugs takes centre stage at ASCO
https://pharmaphorum.com/news/high-cost-cancer-drugs-takes-centre-stage-asco/
ASCO17
Puma gains as Roche breast cancer combo disappoints
ASCO serves up shock as Roche’s data disappoints
Lynparza first PARP drug to show promise in breast cancer
Data sets AZ up to file Lynparza in new indication
AZ highlights data from next-gen oncology drugs at ASCO
Tesara and Takeda among other companies to publish data.
ASCO 2017: Breast cancer next target for Keytruda
Immunotherapy combinations will be the focus – but attention is shifting towards these agents proving their overall survival benefits.